Mymetics Corp (MYMX)

[bow-tie]

Lanying Du, PhD
Title
Head, Laboratory of Viral Immunology
Member, Lindsley F. Kimball Research Institute

Research on coronaviruses
MERS-CoV vaccines and pathogenic mechanisms. We have identified MERS-CoV spike protein receptor-binding domain (RBD) as an important vaccine target, and demonstrated that MERS-CoV RBD contains a critical neutralizing domain capable of inducing cross-neutralizing antibodies against infection of divergent MERS-CoV strains. Current research focus is to design and develop safe, efficacious, and novel MERS vaccines with low-cost, manufacturing capacity, broad-spectrum efficacy, and enhanced potency, identify their protective mechanisms, and study pathogenic mechanisms of MERS-CoV.
Other coronavirus vaccines and pathogenic mechanisms. We have shown that SARS-CoV-2 and SARS-CoV spike proteins and RBDs are important vaccine targets. We are working on the development of novel spike protein and/or RBD-based vaccines against SARS-CoV-2 (COVID-19), SARS-CoV and other coronaviruses with pandemic potential, study of their protective mechanisms, as well as identification of pathogenic mechanisms of these coronaviruses.
Therapeutic antibodies against pathogenic coronaviruses. We have demonstrated that coronavirus spike proteins and RBDs are important therapeutic targets. Current research focus is to design and develop spike protein and/or RBD-targeting novel therapeutic antibodies against emerging coronaviruses with pandemic potential.

https://nybloodcenter.org/lindsley-f-kimball-research-institute/investigators/lanying-du/

https://www.hhs.gov/sites/default/files/nvac_june2020_panel1.pdf?fbclid=IwAR30vPhF5s4cpRzSdZAny7B_IeEhtDnisvK_H31_KxyFCCIFAFj1Q3QFbjs